News | January 09, 2026
Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Subscribe To Our Newsletter & Stay Updated
